Precision Bioanalysis for Therapeutic Protein Quantification.

What is the typical sensitivity and dynamic range for a custom ELISA for a novel LNP-mRNA therapeutic?

A: Sensitivity targets are typically in the low pg/mL to ng/mL range, contingent on the quality of the antibody pair. A standard dynamic range spans 3-4 logs, which is sufficient to capture the full dose-response curve from Cmax to washout in most preclinical models.

How do you mitigate matrix effects from serum or tissue homogenates in the assay?

A: We employ a systematic approach using spike-and-recovery and linearity-of-dilution experiments in multiple lots of pooled matrix. Mitigation strategies include optimizing sample dilution factors, selecting specialized assay buffers, and evaluating blocking agents to minimize non-specific binding.

What is the standard validation process for a custom ELISA intended for GxP-compliant preclinical studies?

A: Our validation protocol is aligned with regulatory expectations and assesses accuracy, precision (intra- and inter-assay), selectivity, specificity, linearity, and stability (freeze-thaw, short-term, long-term). All procedures are executed within our GxP framework to ensure data integrity for IND-enabling studies.

Can this assay be adapted to quantify protein expression in different tissues beyond serum?

A: Yes. The assay is developed for adaptability. We establish and validate specific tissue homogenization protocols to ensure efficient protein extraction and normalize results to total protein content. This allows for direct comparison of expression levels across tissues like the liver, spleen, and lung.

Quantifying the in vivo protein expression from an LNP-delivered mRNA therapeutic requires a highly specific and sensitive bioanalytical method. Off-the-shelf ELISA kits are often inadequate for novel therapeutic proteins, necessitating custom assay development. A purpose-built ELISA provides the required analytical performance to accurately measure transient protein expression, establish dose-dependent PK/PD relationships, and confirm target engagement in relevant tissues. This bioanalytical data directly supports the advancement of LNP-mRNA programs toward a successful IND submission.

Integrating Bioanalysis with Preclinical Program Goals

A validated ELISA provides direct evidence of a therapeutic’s biological activity. For LNP-mRNA programs, this data is used to connect dose level and delivery efficiency to a quantifiable pharmacodynamic effect.

Recent studies highlight the importance of this connection. For example, demonstrating that an LNP-mRNA therapy can produce a functional enzyme to correct a metabolic deficiency requires quantifying that protein’s expression to correlate it with downstream biomarker changes (PMID: 39001827). Similarly, evaluating next-generation delivery platforms, such as siloxane-incorporated lipid nanoparticles, depends on a sensitive assay to confirm that enhanced cellular uptake translates directly to higher protein expression in target tissues (PMID: 39354147). This quantitative data provides direct proof of mechanism and supports platform validation.

At Franklin Biolabs, our >100,000 sq ft GxP-compliant facility is designed to support these integrated programs. Our bioanalytical services are a key component in our clients’ average 18-24 month IND timeline. While the Franklin Biolabs brand was established in 2024, our scientific teams have maintained a 100% IND-enabling success rate since 2019. All programs involving in vivo research are conducted with strict adherence to the 3Rs principles of Animal Welfare.